Immunome, Inc. (IMNM) - Stock Analysis
Last updated: Apr 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Extremely liquid ⢠High cash burn ⢠Minimal revenue IMNM has a very strong liquidity and low leverage but is burning substantial cash with negligible revenue, persistent operating losses, and reliance on financing, making its market valuation appear disconnected from current fundamentals.
Price Behavior
Key Price Behavior Insights: ⢠Modest upside ⢠Choppy action ⢠Buyer rebound Support Level: $20.30, lower support $19.30 Resistance Level: $22.40â$22.50 IMNM is modestly bullish last month, trading about 5% above its last-month SMA with clear support near $20.30 (and a lower $19.30 floor) and immediate resistance at $22.40â$22.50, though the shallow, choppy rally implies limited conviction and pullback risk.
Sentiment & News
Key News Insights: ⢠Clinical breakthrough ⢠NDA timing ⢠Insider activity Immunome reported positive phase 3 RINGSIDE results and plans a Q2 2026 NDA for varegacestat that spurred a stock jump, while concurrent employee option grants and notable insider sales signal mixed corporate signals.
AI Summary
IMNM has shifted from a speculative platform play to a binary, nearâterm commercialization bet hinging on NDA approval and successful launch of varegacestat, making regulatory review and launch execution the decisive value drivers. Monitor the NDA timeline/label, payer access assumptions, and shareâcount dilution/cashâraise cadence closelyâany adverse outcome or heavier-than-expected dilution would sharply compress perâshare value.
Description
Immunome, Inc. is a biopharmaceutical firm that discovers and develops monoclonal antibody therapeutics for oncology and infectious diseases. Its lead oncology candidate, IMM-ONC-01, targets the IL-38 tumor-derived immune checkpoint implicated in tumor immune evasion, and the company also maintains an antibody cocktail program for SARS-CoV-2. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 17 | Dec 24 | IMNM | Immunome, Inc. | Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity. | Closed | +12.9% |